Koers Vertex Pharmaceuticals Incorporated
Aandelen
VRTX
US92532F1003
Biotechnologie & Medisch Onderzoek
Geschatte realtime
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
478,6 USD | -0,98% | +0,98% | +17,87% |
Omzet 2024 * | 10,75 mld. 10,03 mld. | Omzet 2025 * | 11,67 mld. 10,88 mld. | Marktkapitalisatie | 125 mld. 116 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 3,96 mld. 3,69 mld. | Nettowinst (verlies) 2025 * | 4,46 mld. 4,16 mld. | EV/omzet 2024 * | 10,3 x |
Nettoliquiditeiten 2024 * | 13,97 mld. 13,03 mld. | Nettoliquiditeiten 2025 * | 18,59 mld. 17,33 mld. | EV/omzet 2025 * | 9,09 x |
K/w-verhouding 2024 * |
32,1
x | K/w-verhouding 2025 * |
28,4
x | Werknemers | 5.400 |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 99,9% |
Recentste transcriptie over Vertex Pharmaceuticals Incorporated
1 dag | -0,98% | ||
1 week | +0,98% | ||
Lopende maand | +5,33% | ||
1 maand | +11,55% | ||
3 maanden | +15,71% | ||
6 maanden | +34,61% | ||
Lopend jaar | +17,87% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 51 | 01-02-17 | |
Jeffrey Leiden
CHM | Chairman | 68 | 08-07-09 |
Charles Wagner
DFI | Director of Finance/CFO | 56 | 10-04-19 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Alan Garber
BRD | Director/Board Member | 68 | 08-06-17 |
Jeffrey Leiden
CHM | Chairman | 68 | 08-07-09 |
Bruce Sachs
BRD | Director/Board Member | 64 | 01-01-98 |
Naam | Gewicht | Volume | Vaira. 1 jan. | belegger rating |
---|---|---|---|---|
7.67% | 0 M€ | 0,00% | - | |
7.08% | 0 M€ | 0,00% | - |
Datum | Koers | Variatie | Volume |
---|---|---|---|
11-06-24 | 479,8 | -0,72% | 87 485 |
10-06-24 | 483,3 | +0,05% | 1 253 805 |
07-06-24 | 483 | -0,51% | 944 440 |
06-06-24 | 485,5 | +0,52% | 1 263 810 |
05-06-24 | 483 | +1,70% | 1 196 706 |
uitgestelde koers Nasdaq, 11 juni 2024 om 16:13 uur
Meer koersenHerzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
+17,87% | 125 mld. | |
+14,43% | 108 mld. | |
-7,40% | 23,64 mld. | |
+2,01% | 22,39 mld. | |
-12,02% | 17,78 mld. | |
-41,74% | 16,43 mld. | |
-15,24% | 16,34 mld. | |
+0,59% | 13,56 mld. | |
+24,93% | 11,59 mld. | |
+87,69% | 9,66 mld. |